Predictive biomarkers for the efficacy of nivolumab as≥ 3rd-line therapy in patients with advanced gastric cancer: A subset analysis of ATTRACTION-2 phase III trial

UPDATES IN THE UNDERSTANDING AND MANAGEMENT OF THYROID CANCER

314 p | 91 | 18

Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: A phase II efficacy and biomarker study

13 p | 7 | 3

Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer

13 p | 6 | 2

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

13 p | 3 | 2

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

9 p | 9 | 1

Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma

10 p | 4 | 1

Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer

11 p | 10 | 1

Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer

10 p | 10 | 1